Tofacitinib Brands

Pfizer's oral JAK inhibitor (tofacitinib), FDA approved November 6, 2012, as the first JAK inhibitor approved in the United States, indicated for rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, juvenile idiopathic arthritis, and ankylosing spondylitis, subject to a strengthened black box warning in September 2021 following the ORAL Surveillance trial showing increased risks of serious cardiovascular events, cancer, blood clots, and death compared to TNF inhibitors.